Silence Therapeutics
Silence Therapeutics PLC is a British clinical-stage biotechnology enterprise developing targeted RNA interference (RNAi) therapeutics utilizing its proprietary mRNAi GOLD platform. The company designs short interfering RNA (siRNA) molecules to selectively silence disease-causing genes in the liver, advancing clinical candidates including zerlasiran (SLN360) for cardiovascular disease driven by high lipoprotein(a) and divesiran (SLN124) for polycythemia vera. Principal revenue is driven through research collaboration milestone payments, strategic partnerships with Hansoh and AstraZeneca, and capital raises prior to commercial authorization. Core end markets encompass cardiology medical centers, hematology hospital institutes, and cardiovascular prescription patients globally. Silence Therapeutics holds an innovative pioneer position in the biopharmaceutical sector for liver-targeted siRNA gene silencing therapeutics. The corporation is headquartered in London, United Kingdom, and its ADSs trade on the Nasdaq Global Market.
2 of the funds FundTelligence covers report a position in Silence Therapeutics.
- Legal name
- SILENCE THERAPEUTICS
- Sector
- Health Care
- Country
- United Kingdom
- Funds holding it
- 2
- Exposure themes
- Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics
Funds holding Silence Therapeutics
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.0 % (partially disclosed portfolio, June 2026)